ReviewJournal of gynecologic oncology2017
Update on immune checkpoint inhibitors in gynecological cancers.
Review in Journal of gynecologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.Radiation oncology (London, England) · 2019Trial
- Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.Scientific reports · 2018Trial
- Cervical cancer in the modern era: cutting-edge strategies for diagnosis and treatment.Japanese journal of radiology · 2026Review
- A warning to young women: a case of giant ovarian mature cystic teratoma with squamous cell carcinoma transformation in a 22-year-old female and analysis of its molecular features.American journal of cancer research · 2026Article
- Prevalence of Mismatch Repair Gene Defects by Means of Immuno-histochemistry Staining for MMR Proteins in Endometrial Cancer.Journal of obstetrics and gynaecology of India · 2025Article
- Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.EClinicalMedicine · 2025Article
- Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review.Medical oncology (Northwood, London, England) · 2024Review
- Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype.Frontiers in oncology · 2023Review
- Article
- The Alterations of Serum IgG Fucosylation as a Potential Additional New Diagnostic Marker in Advanced Endometriosis.Journal of inflammation research · 2022Article
- Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma.BMC cancer · 2021Article
- The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives.Pharmaceutics · 2021Review
- Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.Journal for immunotherapy of cancer · 2021Article
- PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.Cancer immunology, immunotherapy : CII · 2021Article
- Impact of anatomic site on antigen-presenting cells in cancer.Journal for immunotherapy of cancer · 2020Review
- Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2020Article
- Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy.Journal of clinical medicine · 2020Article
- The emerging role of epigenetic therapeutics in immuno-oncology.Nature reviews. Clinical oncology · 2020Review
- TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.Journal of immunology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy targeting the immune checkpoint receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell-death 1 (PD-1), and programmed cell-death ligand 1 (PD-L1) have demonstrated clinical activity in a wide variety of tumors, including gynecological cancers. This review will focus on the emerging clinical data on the therapeutic role of immune checkpoint inhibitors, and potential strategies to enhance the efficacy of this class of compounds, in the context of gynecological cancers. It is anticipated that future biomarker-directed clinical trials will provide further insights into the mechanisms underlying response and resistance to immunotherapy, and help guide our approach to designing therapeutic combinations that have the potential to enhance the benefit of immunotherapy in patients with gynecologic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.